Other

Cypros Pharmaceutical Corp.

Questcor Pharmaceuticals, Inc.

Angel K Markov

Paul J Marangos

Anthony W Fox

Fructose-1,6-diphosphate (FDP) has been shown, in double-blinded controlled clinical trials on patients with sickle cell anemia, to substantially reduce the pain suffered by such patients during the recurrent ischemic crises that are caused by red blood cell sickling. Tests on patients who have been hospitalized for such crises demonstrated that when they received an intravenous injection of FDP, they reported substantially lower pain levels during their hospital stays than control groups that received identical treatment without any FDP. Apparently, FDP has never previously been used or even tested in human clinical trials, to treat sickle cell anemia. In addition, FDP has never previously been reported to have any analgesic (pain-reducing) activity.

Treatment of sickle cell anemia crises with fructose-1,6-diphosphate as an analgesic drug

Treatment of sickle cell anemia crises with fructose-1, 6-diphosphate as

When fructose-1,6-diphosphate (FDP) is used as an inotropic drug in patients who have undergone surgery involving cardiopulmonary bypass, it can increase the pumping strength of a struggling heart, without increasing the heartbeat rate. As such, FDP can reduce the dosages of (and in some some cases eliminate the need for) other inotropic drugs such as dobutamine, epinephrin, or amrinone lactate, which have undesired and potentially dangerous side effects, mainly involving increasing the heartbeat rate, which imposes substantial additional stresses on hearts that are struggling to regain strength after cardiopulmonary bypass surgery.

Use of fructose-1 6-diphosphate as an inotrope drug after

Fructose-1,6-diphosphate (FDP), a sugar-phosphate compound, can be useful in treating asthma, when administered as an inhalable drug, either by itself or as a component of a mixed formulation. On a cellular level, inhalable FDP appears to offer at least four beneficial effects for asthma sufferers: (1) it reduces histamine release by activated mast cells; (2) it suppresses production of oxygen free radicals by polymorphonuclear cells; (3) it helps suppress the activation and proliferation of T-lymphocytes; and, (4) it helps reduce the expression of interleukin compounds by T-lymphocytes. All four effects have been measured and shown to occur in animal and/or human tests, and these effects render FDP likely to help reduce and retard the progressive worsening of asthma that occurs in many sufferers. In addition, when tested in inhalable form on humans, FDP was shown to increase bronchial flow rates. All of these effects are beneficial, and can help asthma patients treated with FDP use asthma-control drugs which impose less stress on the user than more potent, aggressive asthma-control drugs.

Treatment of asthma with fructose-1,6-diphosphate

This invention discloses a method of using fructose-1,6-diphosphate (FDP) to help suppress the rejection of internal organs such as kidneys, hearts, etc. At least three major advantages of FDP in conjunction with organ transplants have been identified: (1) FDP can help reduce the unwanted proliferation of certain types of stimulated lymphocytes which would otherwise pose a risk of attacking the non-self cells in the transplanted organ; (2) FDP can also potentiate the effectiveness of cyclosporine as a transplant-protecting immunosuppressant, thereby allowing a reduction in CSA dosages, which in turn can reduce the likelihood and the severity of toxic side effects and other dangers of CSA treatment; (3) FDP can also reduce the amount of damage inflicted on an organ during the removal and storage steps required in organ transplantation.

Synergistic administration of cyclosporine and fructose diphosphate

The invention relates to methods of treatment of patients with heat disorders using fructose-1,6-diphosphate.

Use of fructose-1,6-diphosphate for treating myocardial infarction

The invention relates to methods of treatment of patients with heart disorders and methods of preserving stored blood using fructose-1,6-diphosphate.

Method of preserving blood

Fructose-1,6-diphosphate is administered intravenously to a mammalian subject experiencing adult respiratory distress syndrome (ARDS) in an amount sufficient to inhibit pulmonary microvascular damage.

Treatment of adult respiratory distress syndrome (ARDS) using fructose

The invention relates to the treatment of heart disorders. Disruption of heart action or occulision of heart artery results in oxygen deprivation and aerobic metabolism ceases. Unless effective treatment is administered acidosis renders anaerobic metabolism inactive and irreversible tissue damage occurs. Fructose-1,6-diphosphate is used as a therapeutic agent for treating mammalian subjects experiencing myocardial infection in order to prevent ischemic tissue from irreversible tissue damage.

Growing community of inventors

Jackson, MS, United States of America

Angel K Markov